Mayo Clinic and Thermo Fisher Scientific launched Precure, LLC, to study biological changes that occur before disease symptoms emerge.
2
Precure plans to generate molecular data from 1 million biospecimens and link it with clinical information collected over several years.
3
The initiative will combine proteomic, genomic, and longitudinal clinical data and use artificial intelligence and analytics to identify biological patterns.
4
Thermo Fisher will contribute proteomics expertise and technologies, including the Olink Explore HT platform and Thermo Scientific Orbitrap Mass Spectrometry.
5
Mayo Clinic will hold a majority stake, and financial returns will be reinvested in its nonprofit missions of patient care, research, and education.
